Map of China's Pharmaceutical Innovation City, Shaoxing, Shanghai Bridgehead.

Shaoxing's pharmaceutical industry innovation should also start from the listed companies.
According to our reporter statistics, as of the close of the last trading day of 2019, Shaoxing has nine listed pharmaceutical companies, with a total market value of 87.137 billion yuan, ranking 16th in the country.
of the nine companies, the top three by market capitalization were Xinanda and Cheng, Zhejiang Pharma 12.88446 billion yuan and Beijing New Pharmaceuticals 7.785 billion yuan.
these three companies account for 90% of the total market value of Shaoxing-listed pharmaceutical companies.
and from the sub-sector, Shaoxing's listed pharmaceutical enterprises innovation strength is not outstanding, mainly to raw materials and traditional Chinese medicine.
Zhejiang Pharmaceuticals, Ang Likang and Xinhe as raw materials pharmaceutical enterprises, Huatong Pharmaceuticals and the Chinese old name Zhejiang Zhenyuan for Chinese medicine enterprises, in addition to chemical preparations enterprises Asia Pacific Pharmaceuticals and Beijing New Pharmaceuticals, as well as consulting enterprises innovative medical.
Beijing-New Pharmaceutical Industry is a classic example of low-end raw materials and pharmaceutical enterprises transforming generic pharmaceutical enterprises.
in the 2018 volume procurement, Jingxin Pharmaceuticals exclusive bid, its Swiss suvastatin calcium tablets, benzodiazepine tablets and left ethyl lasitan tablets in exchange for the price, in 2019 the sale of finished drugs reached 2.192 billion yuan, an increase of 30.59 percent year-on-year.
the nine listed pharmaceutical companies of the most noteworthy is the new and cheng.
its starting from chemical raw materials, in 2004 as the first domestic small and medium-sized board shares listed on the Shenzhen Stock Exchange, the development has become China's chemical API giant, and with a market value of 49.978 billion yuan occupied the Shaoxing listed pharmaceutical companies half of the wall.
listed companies can not reflect the full strength of Shaoxing, Shaoxing's pharmaceutical innovation also depends on the construction of Shaoxing Binhai New Area in 2010.
growing innovative drug research and development companies often reflect a region's innovation prospects.
June 2018, developed by Gonowei, China's first local original research anti-hepatitis C innovation drug Gonowei was approved for listing, and in early 2019, a new drug, ATG-010, developed in cooperation with Deqi Pharmaceuticals to treat relapsed refractive multiple myeloma, was approved for clinical Chinese mainland, and in July of the same year, the product was approved for sale in the United States.
Coly Pharmaceuticals is headquartered in Hangzhou, but its research and development subsidiary of Gonowei is located in Shaoxing Binhai New Area.
Deqi Pharmaceutical headquarters is also located in Shaoxing Binhai New Area.
Shaoxing Binhai New Area Industrial Cluster Zone was established in July 2010, is the key area of Zhejiang Province to build a marine economic development belt, promote the construction of large-scale large-scale industrial projects, zhejiang Province is also one of the 14 provincial industrial clusters and key development zones (parks) of the "12th Five-Year Plan" key layout of Zhejiang Province.
mentioned pharmaceutical innovation, the country's premier city is Shanghai.
ranked first in China's urban pharmaceutical competitiveness rankings in 2017 with a total market capitalization of 345.8 billion yuan.
In terms of pharmaceutical innovation, Shaoxing is significantly weaker than Shanghai.
but "in its place to seek its own business", Shaoxing's pharmaceutical innovation and development can not be separated from Shanghai, attracting Shanghai's pharmaceutical industry, technology and talent radiation is the only way to develop Shaoxing pharmaceutical bio-industry.
, so, as the bridgehead of Shanghai, Shaoxing's unique advantages? How should Shaoxing "rise up" in the cities of the Yangtze River Delta?
Origin For Shaoxing more than two thousand years of ancient city history, the pharmaceutical industry that only began to rise in 1958 is a new industry in Shaoxing.
similar to the development of the general city, early, a number of low-grade chemical factory and traditional Dan, pills, paste, bulk medicine plant in Shaoxing has been rising.
the early days of reform and opening up, Shaoxing city gradually formed a number of Zhejiang medicine, Zhejiang Zhenyuan and other traditional pharmaceutical enterprises.
1998, Shaoxing Municipal Government proposed the goal of cultivating the pharmaceutical industry into a new pillar industry, and issued "one factory, one policy" and "one product, one policy" and other preferential policies.
so far, Xinchang Pharmaceutical Factory, Zhenyuan Pharmaceutical, Yadong Pharmaceutical and other traditional pharmaceutical companies cast shaoxing City pharmaceutical industry development foundation.
traditional pharmaceutical companies occupy the vast majority of Shaoxing pharmaceutical industry" Jiangshan.
, at the end of the 20th century, Xinchang Pharmaceutical Factory, Xinchang Synthetic Chemical Plant, Zhenyuan Pharmaceutical Co., Ltd., Zhejiang Yadong Pharmaceutical Co., Ltd., Zhejiang Xinguang Pharmaceutical Factory, Zhejiang Jingxin Pharmaceutical Factory 6 enterprises accounted for 84% and 97.8% of the total pharmaceutical industry in the city, respectively.
at the same time, Zhejiang Province is facing a more severe development bottleneck.
the first decade of the 21st century, Zhejiang Province's pharmaceutical industry enterprises from about 400 to 543, but the total output value of the pharmaceutical industry growth rate is slowly declining, which shows that the increase in pharmaceutical enterprises brought only scale expansion, rather than technological progress and innovation.
based on the lack of innovation in the province, in July 2003, the provincial government of Zhejiang Province put forward eight strategies for future development, namely, the "Eight eight strategies".
clearly put forward "to further develop Zhejiang's location advantages, take the initiative to connect with Shanghai, and actively participate in the Yangtze River Delta region exchanges and cooperation."
under this paving, Shaoxing City to develop and build Shaoxing Binhai New Area of the original idea formed.
2010, the Zhejiang provincial government officially approved the "Shaoxing Binhai Industrial Cluster Development Plan", the plan states that "with the riverside area as the core, in accordance with the principle of 'overall planning, shard promotion, innovation system, joint construction of the joint efforts', the city's efforts to develop and build Shaoxing's last piece of treasure land."
" Investment and talent introduction Shaoxing Binhai New Area pharmaceutical industry construction is the key to the introduction of talent, and the introduction of talent is mainly based on two aspects: close to Shanghai and business environment.
since ancient times, "transportation" has been a necessary condition for the commercial strength of the city, the natural geographical advantages make Shaoxing Binhai New Area in undertaking Shanghai is better.
from the map, Shaoxing Binhai New Area is located in the northern part of Shaoxing City along the Yangtze River, east of Changtai high-speed, Beilun deep-water port, south of Hangzhou high-speed, Hangzhou-Hangzhou Canal runs through it.
Shaoxing has fully integrated into Shanghai's "1.5-hour" economic circle: 15 minutes to Hangzhou Xiaoshan Airport, 45 minutes to Ningbo city, Jiashao Bridge across the Yangtze River, directly to Shanghai.
has been located in Shaoxing Binhai New Area since 2017, Deqi Pharma relies on the location advantages of Shaoxing and Shanghai to make full use of the advantages of both places to promote the development of the company's clinical research.
" Binhai New Area is located between Shanghai, Hangzhou, Ningbo, the location advantage is outstanding, to Shanghai only 1.5 hours drive.
Well-developed infrastructure in Binhai New Area has also helped Deqi achieve a business extension from new drug research and development to product production.
"de Qi pharmaceutical in an interview with this newspaper.
not only that, Jiashao Bridge can also be north of Shanghai and Su, south of Wentai, East Ningbo, West Hangzhou, Binhai New Area in 1.5 hours direct to Shanghai on the basis of the future or will become an important transportation hub along the Yangtze River.
the dual support of infrastructure and the reward mechanism of the management committee, it provides an active advantage for the investment of Shaoxing Binhai New Area.
since the investment of 7.8 billion yuan Changhai BioIndustrial Park was completed, in ten years, A number of innovative pharmaceutical enterprises such as Clari, Deqi, and Yuehai Baio have settled in Binhai New Area.
to leave talent, infrastructure to keep up, housing, schools, commercial streets, parks, administrative sub-offices, etc. , can not be less.
since ancient Jiangsu, Zhejiang's livable conditions have never been questioned, "there is heaven, there is Suhang" has been accompanied by the development of the two provinces, Shaoxing Binhai New Area is not outside this.
the spatial structure of Binhai New Area is referred to as "three zones, two zones, one heart", which refers to the coastal landscape belt and the riverside landscape belt along the CaoYu River and the Yangtze River, Cao Yujiang river along the river greening has become the natural advantages of the development of the Binhai New Area culture, tourism service industry;
in education, in 2019, Zhejiang Post and Telecommunications Vocational and Technical College Binhai New Area Campus was officially opened, Binhai New Area ushered in the first university.
Binhai New Area's large shopping malls are located in the "one heart" area, also within 2 km of Zhejiang Post and Telecommunications Vocational and Technical College, which also includes residential areas, financial institutions and administrative agencies. The improvement of the infrastructure of
constitutes the basis for attracting talents from Binhai New Area, further increasing the attraction and enhancing innovation is also the incentive mechanism of Binhai New Area Management Committee: each 1.1 innovative drug approval can be awarded 10 million yuan.
innovation still needtime fermentation At present, Shaoxing Binhai New Area has initially formed the three industries of chemical preparations, biotechnology drugs and pharmaceutical equipment.
But for Shaoxing itself, the total market capitalisation of listed pharmaceutical companies is Rmb87.1bn, a far cry from the total market capitalisation of more than Rmb200bn in Hangzhou, the provincial capital.
from the point of view of specific enterprises, Shaoxing's listed pharmaceutical enterprises are mainly in Zhejiang Pharmaceutical, Xinhecheng and Beijing New Pharmaceuticals and other raw materials and generic drugs enterprises.
and located in Hangzhou' listed pharmaceutical companies, in addition to the huge volume of East China Pharmaceuticals, Beida Pharmaceuticals, Tyger Medical and other research and development-type pharmaceutical enterprises are more prominent performance.
from this level, Shaoxing's listed pharmaceutical companies' innovation power does not seem ideal.
from the perspective of globalization, Shaoxing Binhai New Area's two most prominent innovative pharmaceutical companies - Goli and Deqi, the two companies are set and layout are global-oriented, for foreign cooperation and pay attention to the progress of global innovation medicine has a great demand.
but the eyes of foreign investors do not seem to be aimed at Shaoxing.
2010, merchadon, Pfizer, Lilly and other foreign pharmaceutical companies have built research and development centers in Hangzhou, not only Hangzhou as the provincial capital city advantages, and East China Pharmaceuticals, Tyger Pharmaceuticals and other enterprises cooperation is not without relationship.
for enterprises, industrial agglomeration in the enterprise innovation chain, talent, projects and capital resources will bring can not be ignored, Hangzhou's industrial agglomeration has brought billions of yuan level of foreign-funded enterprises, Shaoxing gathered mainly in the growth of innovative pharmaceutical research and development enterprises, it can be seen that Shaoxing pharmaceutical industry development in investment and the growth of established enterprises still need a lot of space.
Jiashao Bridge, Hangzhou high-speed transportation hub network, primary and secondary schools and large shopping malls infrastructure and the two rivers along the green environment to attract high-end talent and investment conditions have been formed, but from the overall market value and innovation ability of pharmaceutical companies, Shaoxing also needs space for development, innovative pharmaceutical research and development enterprises are still growing, and currently has not attracted a number of foreign-funded enterprises to settle.
the formation of a unique advantage of the development characteristics and the development of the innovation of existing enterprises need time is still a problem facing Shaoxing.
.